HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Extracellular CIRP decreases Siglec-G expression on B-1a cells skewing them towards a pro-inflammatory phenotype in sepsis.

AbstractBACKGROUND:
Sepsis is a life-threatening disease syndrome caused by a dysregulated host response to infection and injury. Extracellular cold-inducible RNA-binding protein (eCIRP) acts as a damage-associated molecular pattern. Peritoneal cavity (PerC) B-1a cells attenuate inflammation and tissue injury by spontaneous releasing natural IgM and IL-10. Sialic acid-binding immunoglobulin-type lectin-G (Siglec-G) is a CD33-related receptor highly expressed in B-1a cells to serve critical immunoregulatory functions. In sepsis, B-1a cell numbers in PerC are decreased. We hypothesized that eCIRP causes the reduction of PerC B-1a cells and alters their function during sepsis.
METHODS:
Sepsis was induced in WT and CIRP-/- mice by cecal ligation and puncture (CLP). PerC washout cells were collected and B-1a cells and Siglec-G were assessed by flow cytometry. Mice were i.p. injected with recombinant murine (rm) CIRP and after 20 h, Siglec-G expression in PerC B-1a cells were assessed. PerC B-1a cells were treated with rmCIRP for 4 h and Siglec-G expression was assessed. PerC B-1a cells were pre-treated with anti-Siglec-G Ab and then after stimulated with rmCIRP for 24 h, IL-6 levels in the culture supernatants were assessed.
RESULTS:
eCIRP levels in the PerC were elevated in septic mice. In WT mice, the frequencies and numbers of total and Siglec-G+ B-1a cells in the PerC were significantly decreased in the CLP group compared to sham group, whereas in CIRP-/- mice, their frequencies and numbers in sepsis were significantly rescued compared to WT septic mice. Mice injected with rmCIRP showed decreased frequencies and numbers of total and Siglec-G+ PerC B-1a cells compared to PBS-injected mice. In vitro treatment of PerC B-1a cells with rmCIRP demonstrated significant reduction in Siglec-G mRNA and protein compared to PBS group. PerC B-1a cells treated with anti-Siglec-G Ab had significantly higher production of IL-6 in response to rmCIRP compared to IgG control. Anti-Siglec-G Ab treated B-1a cells co-cultured with macrophages produced significantly higher levels of IL-6, and TNF-α, and lower levels of IL-10 compared to IgG-treated B-1a cells and macrophage co-cultures stimulated with rmCIRP.
CONCLUSION:
eCIRP reduces PerC B-1a cell pool and skews them to a pro-inflammatory phenotype by downregulating Siglec-G expression. Targeting eCIRP will retain Siglec-G expressing B-1a cells in the PerC and preserve their anti-inflammatory function in sepsis.
AuthorsWilliam Royster, Hui Jin, Ping Wang, Monowar Aziz
JournalMolecular medicine (Cambridge, Mass.) (Mol Med) Vol. 27 Issue 1 Pg. 55 (05 31 2021) ISSN: 1528-3658 [Electronic] England
PMID34058975 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Biomarkers
  • Cirbp protein, mouse
  • Cytokines
  • Inflammation Mediators
  • RNA-Binding Proteins
  • Receptors, Antigen, B-Cell
  • Sialic Acid Binding Immunoglobulin-like Lectins
  • Siglecg protein, mouse
  • Toll-Like Receptor 4
Topics
  • Animals
  • Ascitic Fluid (metabolism)
  • Biomarkers
  • Cytokines (blood, genetics, metabolism)
  • Disease Models, Animal
  • Extracellular Space (metabolism)
  • Gene Expression Regulation
  • Immunophenotyping
  • Inflammation Mediators (metabolism)
  • Macrophages (immunology, metabolism)
  • Male
  • Mice
  • Mice, Knockout
  • Phenotype
  • RNA-Binding Proteins (genetics, metabolism)
  • Receptors, Antigen, B-Cell (genetics, metabolism)
  • Sepsis (diagnosis, etiology, metabolism)
  • Sialic Acid Binding Immunoglobulin-like Lectins (genetics, metabolism)
  • Toll-Like Receptor 4 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: